BRCA1 and cancer: Furthermore, our finding that VNLG-152R potently suppress the expressions of peIF4E and p4E-BP1 in TNBC in vitro and in vivo is exciting as the ‘homogenous expressions’ of these oncogenes are proving to be remarkable cancer targets deemed to be more important with respect to therapeutic targeting than the current well-established oncogenic targets such as PI3k, pAkt, pmTOR, pMAPK, HER2, BRCA1/2, AR/AR-Vs and ERα that are ‘heterogeneously expressed’ in most tumors [68,69,70].